Clinical Trial Update: Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining etoposide capsules plus bevacizumab, iparomlimab, and tuvonralimab for platinum-resistant or platinum-refractory ovarian…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer
• Platinum-refractory Epithelial Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Etoposide (Etoposide)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Fudan University | Conditions: Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING